**Core Concept**
The Revised National Tuberculosis Control Programme (RNTCP) 2010 guidelines categorize tuberculosis patients based on their drug resistance patterns for effective treatment. This categorization is crucial for tailoring treatment regimens to prevent treatment failure, relapse, and the spread of resistant strains.

**Why the Correct Answer is Right**
A patient with only rifampicin resistance is considered to have a category of drug-resistant tuberculosis, but not multi-drug resistant (MDR) tuberculosis. Rifampicin is a critical drug in the treatment of tuberculosis, and resistance to this drug indicates a higher risk of treatment failure. According to the RNTCP 2010 guidelines, patients with rifampicin-resistant tuberculosis are treated under the category of rifampicin-resistant tuberculosis. This category involves the use of a second-line anti-tuberculosis regimen, which includes drugs such as kanamycin, amikacin, or capreomycin, to prevent the spread of resistance.

**Why Each Wrong Option is Incorrect**
* **Option A:** This option is incorrect because it does not accurately represent the RNTCP 2010 guidelines for treating patients with rifampicin resistance.
* **Option B:** This option is incorrect because it does not specify the correct category for patients with rifampicin resistance as per the RNTCP 2010 guidelines.
* **Option D:** This option is incorrect because it implies a more severe form of drug resistance than rifampicin resistance alone.

**Clinical Pearl / High-Yield Fact**
It is essential to remember that rifampicin resistance is a critical indicator of potential treatment failure and the need for second-line anti-tuberculosis regimens. A high index of suspicion for rifampicin resistance should be maintained in patients with recurrent tuberculosis or those who do not respond to standard treatment.

**Correct Answer:** D.